Veterinary Oncology Market Overview
The Veterinary Oncology Market is expanding as companion animals live longer and cancer becomes an increasingly important area of veterinary care. Growing pet humanization, wider pet-insurance coverage, advances in diagnostic technologies, and the development of targeted and immune-based therapies are increasing demand for specialized cancer diagnosis and treatment for animals.
According to the Market Research Future report updated September 10, 2026, the Veterinary Oncology Market was valued at USD 1.86 billion in 2025 and is projected to grow from USD 2.08 billion in 2026 to USD 5.35 billion by 2035, registering a CAGR of 11.08% during 2026–2035. North America accounted for 57.5% of global revenue in 2025, while Asia-Pacific is projected to be the fastest-growing region at a 14.6% CAGR. Surgery represented approximately 43.3% of treatment-modality revenue, while Immunotherapy is forecast to grow at a 12.1% CAGR. Canine patients accounted for approximately 80.7% of the market, while Feline oncology is projected to grow at a 13.7% CAGR. Melanoma held approximately 41.5% of the cancer-type market, while Lymphoma is expected to grow at an 11.9% CAGR.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/reports/veterinary-oncology-market-33291
Key players driving innovation and competitiveness in the Veterinary Oncology Market include:
Zoetis
Elanco Animal Health
Boehringer Ingelheim
Merck Animal Health
IDEXX Laboratories
Dechra Pharmaceuticals
Mars Veterinary Health
Torigen Pharmaceuticals
PetDx
ELIAS Animal Health
The Veterinary Oncology Market is being shaped by the aging companion-animal population, increasing willingness among owners to pursue advanced cancer treatments, and improvements in veterinary specialty infrastructure. Liquid biopsy technologies and AI-assisted imaging are supporting earlier and more detailed cancer detection, while immunotherapy and targeted therapies are expanding treatment options. Regulatory pathways for veterinary therapeutics and increasing comparative-oncology research are also encouraging development of new cancer therapies that may have applications across animal and human medicine.
The Veterinary Oncology Market can be segmented by treatment modality, animal type, cancer type, service type, end user, and diagnostic method. By treatment modality, the market includes Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, and Targeted Therapy. By animal type, it covers Dogs, Cats, Horses, Small Mammals, and Exotic Animals. Cancer categories include Melanoma, Lymphoma, Mast Cell Tumor, Osteosarcoma, and other cancers. Service types include Diagnosis, Treatment, Palliative Care, and Preventive Care, while end users include Veterinary Clinics, Animal Hospitals, and Research Institutions. Diagnostic methods include Biopsy, Blood Tests, Imaging Techniques, and Endoscopy.
Opportunities are emerging through AI-powered diagnostic platforms, liquid biopsy, comparative oncology, personalized immunotherapies, and data-driven veterinary outcomes platforms. Expansion of specialty veterinary infrastructure in Asia-Pacific and Latin America can further increase access to advanced oncology care. Subscription-based decision-support services and longitudinal treatment databases are also creating opportunities for veterinary providers and animal-health companies to improve treatment monitoring and clinical decision-making.
Recent Developments and Market Trends:
AI-powered imaging and pathology platforms are increasingly being explored to support earlier cancer detection and improve diagnostic decision-making in veterinary practices.
Liquid biopsy technologies are expanding opportunities for minimally invasive cancer screening and monitoring, particularly for companion animals.
Immunotherapy and autologous cancer-treatment approaches are gaining attention as veterinary oncology moves toward more targeted and personalized treatment strategies.
Growing pet-insurance coverage in developed markets is helping reduce financial barriers associated with advanced diagnostic procedures, chemotherapy, radiation therapy, and other oncology services.
Comparative oncology research is strengthening collaboration between veterinary and human cancer researchers, supporting the development and evaluation of new therapeutic approaches.
Reasons to Buy the Report:
Understand the market size, growth trajectory, CAGR, and forecast valuation through 2035.
Identify the dominant and fastest-growing treatment, animal-type, and cancer-type segments.
Evaluate North America’s market leadership and Asia-Pacific’s rapid expansion.
Analyze the competitive landscape and strategies of leading veterinary oncology companies.
Assess emerging opportunities in AI diagnostics, liquid biopsy, immunotherapy, comparative oncology, and data-driven care.
Future Outlook:
The Veterinary Oncology Market is expected to maintain strong growth through 2035 as longer companion-animal lifespans, increasing cancer incidence, expanding specialty veterinary infrastructure, and greater willingness to pursue advanced treatment support demand. Surgery is expected to remain the largest treatment modality because it continues to serve as a primary intervention for many solid tumors, while Immunotherapy is projected to be the fastest-growing treatment segment at a 12.1% CAGR as checkpoint inhibitors, cancer vaccines, and personalized therapies advance. Canine patients will continue to represent the largest animal category, accounting for approximately 80.7% of the market in 2025, while Feline oncology is projected to be the fastest-growing animal segment at a 13.7% CAGR as diagnostic availability and owner awareness improve. Melanoma currently represents the largest cancer category at approximately 41.5%, while Lymphoma is expected to experience rapid growth at an 11.9% CAGR as multi-agent treatment protocols and supportive care improve. Veterinary Clinics and Animal Hospitals will remain central to market demand, while Research Institutions are expected to benefit from expanding comparative-oncology programs. North America is expected to retain its leadership with a 57.5% share, supported by established specialty referral networks, pet-insurance penetration, and advanced veterinary infrastructure. Asia-Pacific is projected to remain the fastest-growing region at a 14.6% CAGR, supported by increasing companion-animal ownership, rising healthcare expenditure, and expanding specialty veterinary services. Overall, the Veterinary Oncology Market is projected to reach USD 5.35 billion by 2035 at a CAGR of 11.08%.
➤➤Explore Our Latest Related Reports:
